Brainsway Ltd. Form 6-K Summary
Business Context and Reporting Period
Company: Brainsway Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Filed: December 9, 2019
Reporting Period: This filing serves as a Notice and Proxy Statement for the Annual General Meeting of Shareholders scheduled for January 13, 2020. It does not contain financial results for a specific reporting period but rather proposes corporate governance actions and executive compensation approvals.
Key Financial Metrics
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. Financial performance data for the fiscal year ended December 31, 2018, is referenced as being available in the Company's Registration Statement on Form F-1 but is not included in this document.
Capital Structure: As of the record date (December 16, 2019), the Company had 22,236,368 Ordinary Shares outstanding.
Material Changes and Corporate Actions
The filing outlines several material changes and proposals to be voted on by shareholders:
- Executive Leadership Transition: Appointment of Christopher R. von Jako, Ph.D., as President and CEO, effective January 1, 2020, succeeding Dr. David Zacut (Interim CEO).
- Board Composition: Re-election of Dr. David Zacut and Mr. Avner Hagai, and election of Mr. Avner Lushi as directors.
- Compensation Policy Amendments: Proposed amendments to allow flexibility in hiring executives outside Israel, including up to 12 months prior notice periods for non-Israeli officers.
- Articles of Association: Proposed removal of the staggered board mechanism and reduction of the notice period for shareholder director nominations from 60 to 45 days.
Guidance, Outlook, and Management Commentary
Strategic Outlook: Management emphasizes a strategic transition to U.S.-based leadership to support the Company's next phase of growth. Dr. von Jako is described as a science-driven executive with over 25 years of experience in global medical technology.
Executive Compensation Details:
- CEO (Dr. von Jako): Annual base salary of $350,000 (Year 1) with 3% annual increases. Performance bonus up to six months' salary. Equity grant of 240,000 RSUs in four tranches, contingent on operating plan objectives and relative stock price performance against an industry index.
- Chairman (Dr. Zacut): Monthly consultancy fee of NIS 30,000 (40% capacity) post-re-election. An additional 3-month period (Jan–Mar 2020) at 100% capacity (NIS 75,000/month) to facilitate on-the-job training for the new CEO.
- Directors: Grant of 27,500 options each to independent directors Ms. Eti Mitrany and Mr. Avner Lushi.
Risks and Contingencies: The filing notes that the approval of the CEO's severance and change of control provisions is contingent upon the approval of the amended compensation policy (Proposal 4).
Investor Verification Checklist
- Verify the specific terms of the "Industry Index" to be used for Dr. von Jako's equity performance metrics, as it is to be mutually agreed upon in writing.
- Review the Company's Form F-1 for the most recent audited financial statements (FY 2018) to assess current liquidity and cash burn rates, as this filing contains no financial data.
- Confirm the voting requirements for Proposals 4, 5, and 7, which require a majority of non-controlling shareholders without a personal interest, in addition to a general majority.
- Monitor the transition timeline to ensure Dr. Zacut's consultancy reverts to 40% capacity after March 31, 2020, as proposed.